The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients
Rodríguez-Pintó I., Espinosa G., Erkan D., Shenfel`d I. Yu., Cervera R., Piette J. C., Jacek M., Roca B., Tektonidou M., Moutsopoulos H., Boffa J., Chapman J., Stojanovich L., Veloso M. P., Praprotnik S., Traub B., Levy R., Daryl T., Tan D., Boffa M. C., Makatsariya A. D., Ruano M., Allievi A., You W., Khamastha M., Hughes S., Nilzete L., Menendez S. J., Pacheco J., Boriotti M. F., Dias C., Pangtey G., Miller S., Policepatil S., Larissa L., Marjatta S., Carolyn S., Noortje T., Reiner K., Arteaga S., Leilani T., Langsford D., Niedzwiecki M., Queyrel V., Moroti-Constantinescu R., Romero C., Jeremic K., Urbano A., Hurtado-García R., Kumar D. A., Costedoat-Chalumeau N., Yngvar F., Gomez-Puerta J. A., de M. E., Smith J. P., Zakharova E., Nayer A., Douglas W., Lyndsey R., Blanco V., Vicent C., Natalya K., Damian L., Valentini E., Giula B., Casal M. M., Loperena O. A., Susan Y. R., Imbert G. G., Almasri H., Hospach T., Mouna B., Robles A., Wilson H., Guisado P., Ruiz R., Rodriguez J.
Rheumatology (Oxford, England)
Vol.57, Issue7, P. 1264-1270
Опубликовано: 2018
Тип ресурса: Статья
DOI:10.1093/rheumatology/key082
Аннотация:
Objectives. The objective of this study was to assess the effect that triple therapy (anticoagulation plus CS plus plasma exchange and/or IVIGs) has on the mortality risk of patients with catastrophic APS (CAPS) included in the CAPS Registry. Methods. Patients from the CAPS Registry were grouped based on their treatments: triple therapy; drugs included in the triple therapy but in different combinations; and none of the treatments included in the triple therapy. The primary endpoint was all-cause mortality. Multivariate logistic regression models were used to compare mortality risk between groups. Results. The CAPS Registry cohort included 525 episodes of CAPS accounting for 502 patients. After excluding 54 episodes (10.3[%]), a total of 471 patients with CAPS were included [mean (S.D.) age 38.5 years (17); 68.2[%] female primary APS patients 62[%]]. Overall, 174 (36.9[%]) patients died. Triple therapy was prescribed in 189 episodes (40.1[%]), other combinations in 270 (57.3[%]) and none of those
Ключевые слова:
Antiphospholipid syndrome; Catastrophic antiphospholipid syndrome; Immunoglobulins; Mortality; Plasma exchange; Survival rate; Systemic lupus erythematosus; Treatment; Triple therapy
anticoagulant agent; corticosteroid; immunoglobulin; adult; all cause mortality; anticoagulant therapy; antiphospholipid syndrome; Article; catastrophic antiphospholipid syndrome; cohort analysis; controlled study; female; human; major clinical study; male; mortality rate; mortality risk; outcome assessment; plasma exchange; priority journal; retrospective study; survival; terminal disease
Язык текста: Английский
ISSN: 1462-0332
Rodríguez-Pintó I.
Espinosa G.
Erkan D.
Shenfel`d I. Yu. Ieguda Yulius 1948-
Cervera R.
Piette J. C.
Jacek M.
Roca B.
Tektonidou M.
Moutsopoulos H.
Boffa J.
Chapman J.
Stojanovich L.
Veloso M. P.
Praprotnik S.
Traub B.
Levy R.
Daryl T.
Tan D.
Boffa M. C.
Makatsariya A. D. Aleksandr Davidovich 1944-
Ruano M.
Allievi A.
You W.
Khamastha M.
Hughes S.
Nilzete L.
Menendez S. J. Suso J.
Pacheco J.
Boriotti M. F.
Dias C.
Pangtey G.
Miller S.
Policepatil S.
Larissa L.
Marjatta S.
Carolyn S.
Noortje T.
Reiner K.
Arteaga S.
Leilani T.
Langsford D.
Niedzwiecki M.
Queyrel V.
Moroti-Constantinescu R.
Romero C.
Jeremic K.
Urbano A.
Hurtado-García R.
Kumar D. A. Das A.
Costedoat-Chalumeau N.
Yngvar F.
Gomez-Puerta J. A.
de M. E. Meigs E.
Smith J. P.
Zakharova E.
Nayer A.
Douglas W.
Lyndsey R.
Blanco V.
Vicent C.
Natalya K.
Damian L.
Valentini E.
Giula B.
Casal M. M. Moura M.
Loperena O. A.
Susan Y. R.
Imbert G. G.
Almasri H.
Hospach T.
Mouna B.
Robles A.
Wilson H.
Guisado P.
Ruiz R.
Rodriguez J.
Родрíгуез-Пинтó И.
Еспиноса Г.
Еркан Д.
Шенфельд И. Ю. Иегуда Юлиус 1948-
Cервера Р.
Пиетте Й. C.
Йаcек М.
Роcа Б.
Тектонидоу М.
Моуцопоулос Х.
Боффа Й.
Чапман Й.
Стойанович Л.
Велосо М. П.
Прапротник С.
Трауб Б.
Левy Р.
Дарyл Т.
Тан Д.
Боффа М. C.
Макацария А. Д. Александр Давидович 1944-
Руано М.
Аллиеви А.
Ёу W.
Хамастха М.
Хугхес С.
Нилзете Л.
Менендез С. Й. Сусо Й.
Пачеcо Й.
Бориотти М. Ф.
Диас C.
Пангтеy Г.
Миллер С.
Полиcепатил С.
Ларисса Л.
Марйатта С.
Cаролyн С.
Ноортйе Т.
Реинер К.
Артеага С.
Леилани Т.
Лангсфорд Д.
Ниедзwиеcки М.
Qуеyрел В.
Мороти-Cонстантинесcу Р.
Ромеро C.
Йеремиc К.
Урбано А.
Хуртадо-Гарcíа Р.
Кумар Д. А. Дас А.
Cостедоат-Чалумеау Н.
Yнгвар Ф.
Гомез-Пуерта Й. А.
де М. Е. Меигс Е.
Смитх Й. П.
Захарова Е.
Найер А.
Доуглас W.
Лyндсеy Р.
Бланcо В.
Виcент C.
Наталя К.
Дамиан Л.
Валентини Е.
Гиула Б.
Cасал М. М. Моура М.
Лоперена О. А.
Сусан Y. Р.
Имберт Г. Г.
Алмасри Х.
Хоспач Т.
Моуна Б.
Роблес А.
Wилсон Х.
Гуисадо П.
Руиз Р.
Родригуез Й.
The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients
Текст визуальный непосредственный
Rheumatology (Oxford, England)
Oxford University Press
Vol.57, Issue7 P. 1264-1270
2018
Статья
Antiphospholipid syndrome Catastrophic antiphospholipid syndrome Immunoglobulins Mortality Plasma exchange Survival rate Systemic lupus erythematosus Treatment Triple therapy
anticoagulant agent corticosteroid immunoglobulin adult all cause mortality anticoagulant therapy antiphospholipid syndrome Article catastrophic antiphospholipid syndrome cohort analysis controlled study female human major clinical study male mortality rate mortality risk outcome assessment plasma exchange priority journal retrospective study survival terminal disease
Objectives. The objective of this study was to assess the effect that triple therapy (anticoagulation plus CS plus plasma exchange and/or IVIGs) has on the mortality risk of patients with catastrophic APS (CAPS) included in the CAPS Registry. Methods. Patients from the CAPS Registry were grouped based on their treatments: triple therapy; drugs included in the triple therapy but in different combinations; and none of the treatments included in the triple therapy. The primary endpoint was all-cause mortality. Multivariate logistic regression models were used to compare mortality risk between groups. Results. The CAPS Registry cohort included 525 episodes of CAPS accounting for 502 patients. After excluding 54 episodes (10.3[%]), a total of 471 patients with CAPS were included [mean (S.D.) age 38.5 years (17); 68.2[%] female primary APS patients 62[%]]. Overall, 174 (36.9[%]) patients died. Triple therapy was prescribed in 189 episodes (40.1[%]), other combinations in 270 (57.3[%]) and none of those